Erythropoiesis and Iron Sulfur Cluster Biogenesis by Ye, Hong & Rouault, Tracey A.
Hindawi Publishing Corporation
Advances in Hematology
Volume 2010, Article ID 329394, 8 pages
doi:10.1155/2010/329394
Review Article
Erythropoiesisand Iron Sulfur Cluster Biogenesis
Hong Ye andTracey A.Rouault
Molecular Medicine Program, Eunice Kennedy Shriver National Institutes of Child Health and Human Development at (NIH),
9000 Rockville Pike, Bethesda, MD 20892, USA
Correspondence should be addressed to Tracey A. Rouault, rouault@mail.nih.gov
Received 1 March 2010; Revised 4 June 2010; Accepted 2 August 2010
Academic Editor: Maria R. Baer
Copyright © 2010 H. Ye and T. A. Rouault. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Erythropoiesis in animals is a synchronized process of erythroid cell diﬀerentiation that depends on successful acquisition of iron.
Heme synthesis depends on iron through its dependence on iron sulfur (Fe-S) cluster biogenesis. Here, we review the relationship
betweenFe-Sbiogenesisandhemesynthesisinerythropoiesis,withemphasisontheproteins,GLRX5,ABCB7,ISCA,andC1orf69.
These Fe-S biosynthesis proteins are highly expressed in erythroid tissues, and deﬁciency of each of these proteins has been shown
to cause anemia in zebraﬁsh model. GLRX5 is involved in the production and ABCB7 in the export of an unknown factor that may
functionasagaugeofmitochondrialironstatus,whichmayindirectlymodulateactivityofironregulatoryproteins(IRPs).ALAS2,
the enzyme catalyzing the ﬁrst step in heme synthesis, is translationally controlled by IRPs. GLRX5 may also provide Fe-S cofactor
for ferrochelatase, the last enzyme in heme synthesis. ISCA and C1orf69 are thought to assemble Fe-S clusters for mitochondrial
aconitase and for lipoate synthase, the enzyme producing lipoate for pyruvate dehydrogenase complex (PDC). PDC and aconitase
are involved in the production of succinyl-CoA, a substrate for heme biosynthesis. Thus, many steps of heme synthesis depend on
Fe-S cluster assembly.
1. Erythropoiesis
Erythropoiesis, the manufacture of red blood cells (or
erythrocytes), mainly occurs within bone marrow in human
adults, for review see [1]. In erythropoiesis, there is a
stepwise diﬀerentiation of cell types, beginning with multi-
potent hematopoietic stem cells which successively mature
into common myeloid progenitor cells, proerythroblasts,
erythroblasts, and ﬁnally into mature erythrocytes [2].
Erythropoiesis is stimulated by the hormone, erythropoietin
(EPO), for review see [3], which enhances proliferation and
diﬀerentiation of the erythroid cells by blocking apoptosis of
erythroid progenitors, as is reviewed elsewhere, for review
see [4–8]. Hemoglobinization results from the production
of hemoglobin, which requires synthesis of heme. Heme
is synthesized by an eight step enzyme-catalyzed pathway,
in which the ﬁnal step is the insertion of an iron into
protoporphyrin IX to form a protoheme, for review see
[9,10].Thesubstantialmanufactureofhemeforhemoglobin
in red blood cells consumes 70% of body iron in humans.
Iron homeostasis during erythropoiesis is highly regulated to
synchronize synthesis of heme and globin and to avoid the
potential toxicity caused by accumulation of excess iron or
heme.
2. SystemicIron Metabolism and
Regulation of HepcidinExpressionby
EPOandOther Factors
Iron in food is absorbed in the duodenum, from which it is
releasedintothecirculationviaferroportin,theironexporter
on basolateral membranes of duodenal enterocytes. Most
of the daily iron supply in the human body comes from
phagocytosis of senescent red blood cells by macrophages
in the spleen, liver, and bone marrow. Macrophages recycle
iron by metabolizing heme and releasing the free iron
into the circulation via the membrane-bound ferrous iron
transporter, ferroportin [11–13]. The ferroportin-mediated
release of iron is therefore a key regulation point of systemic
iron metabolism. Hepcidin is a small peptide synthesized
mainly in the liver that modulates the abundance of2 Advances in Hematology
ferroportin at the cellular membrane of cells that release
iron, for review see [14–16]. Hepcidin is the master regu-
lator of systemic iron homeostasis: low levels of hepcidin
increase iron release into plasma, whereas high hepcidin
levels decrease iron release into plasma. The transcription
of hepcidin is complex and is ﬁnely tuned by a number
of diﬀerent signal transduction pathways, for review see
[14, 17–19]. To coordinate iron metabolism to meet the
demands of erythropoiesis, hepcidin expression is regulated
by EPO, the erythropoiesis stimulator, and also possibly
by growth diﬀerentiation factor 15 (GDF15) and twisted
gastrulation (TWSG1), soluble peptides which are directly
produced by erythroblasts [20, 21]. In cultured liver cells
(primary hepatocytes and HepG2), hepcidin transcription
is regulated by EPO, which mediates its eﬀect through
EPO receptor signaling and C/EBP transcription factor [22].
GDF15 secretion from maturing erythroblasts may inhibit
hepcidin mRNA expression in hepatocytes, which would
therefore allow more release of iron into plasma from
the duodenum and macrophages to support erythropoiesis.
However, this potential role of GDF15 remains unproven,
as GDF15 has failed to suppress hepcidin expression in
cellular models [23, 24]. In thalassemia syndromes, GDF15
is overexpressed, and its proposed repression of hepcidin
expression leads to iron overload [20]. TWSG1 protein,
which is also expressed by erythroblast cells, may regulate
hepcidin expression together with GDF15 by interfering
with BMP-mediated hepcidin expression [21], or it may act
independently of GDF15.
3.EffectsofIronHomeostasisonErythropoiesis
Cellular iron homeostasis in mammals is primarily regulated
by the IRP/IRE system, which operates mainly at the
posttranscriptional level. Mammalian cells express two iron
regulatory proteins (IRPs), including IRP1 (annotated as
Aco1 in genome) and IRP2 (annotated as Ireb2 in genome,
but commonly referred to as IRP2), for review see [25, 26].
IRP1 protein functions as a cytosolic aconitase when it
ligates a [4Fe-4S] cluster whereas it is activated to bind to
RNA stem-loops known as iron-responsive elements (IREs)
when it lacks an Fe-S cluster. IRP2 is degraded in iron
replete conditions whereas it is stabilized in cells that are
iron-depleted, and stabilized IRP2 acts as a second IRE-
binding protein. The iron-responsive element (IRE) consists
of a conserved loop (5 -CAGUGN-3 )a tt h ee n do fab a s e -
pairedhelicalstemthatisinterruptedbyanunpaired“bulge”
cytosine. IREs are usually found in the untranslated regions
(UTR) of various mRNAs. When IRP proteins bind to an
IRE in 5 UTR they inhibit translation whereas then they
bind IREs in 3 UTR of the TfR1 transcript, they stabilize the
mRNA.
Erythropoiesis depends on ample iron supplies, and
the process of erythropoiesis is regulated in several ways
by iron metabolism. Erythropoiesis is driven by EPO,
a hormone synthesized mainly in renal interstitial cells.
Hypoxia inducible factor 2α (HIF2α) has a major role in the
transcriptional activation of EPO, as it binds to the hypoxia-
responsive element (HRE) of the EPO gene, and activates
EPO transcription [19,27–30]. Interestingly, HIF2α contains
a5  IRE in its transcript, and therefore HIF2α protein
translation can be repressed when IRE-binding activity is
increased, and this eﬀect seems to be mainly mediated by
IRP1 [31, 32]. In hypoxic cells, both HIF1α and HIF2α
proteins are stabilized, and transcription of their target genes
increases [32]. However, in cells that are also iron deﬁcient,
translation and synthesis of HIF2α would be expected
to be repressed by IRP binding. Although IRP-dependent
repression of HIF2α has not been formally demonstrated to
occurinanimalmodels,thepotentialforrepressionofHIF2α
translation by IRP1 has been demonstrated in vitro [32].
Thus,itislikelythattheFe-Sprotein,IRP1,hasanimportant
role in regulating expression of EPO.
More directly, erythroblasts are themselves signiﬁcantly
dependent on proper iron homeostasis controlled by IRP2
[33, 34] and on successful iron acquisition mediated by
transferrin receptor 1 (TfR1) [35] and mitoferrin-1 (or
SLC25A37) [36, 37], as shown by anemias that develop when
they are deﬁcient in model organisms. IRP2 is the second
iron regulatory protein in mammals, which regulates cellular
iron homeostasis by binding to transcripts that contain
IREs, similar to IRP1 [25] and the IRP2−/− deletion mouse
model manifests microcytic anemia. Studies to address the
cause of anemia have revealed that TfR1 expression in
erythroid precursors of IRP2−/− mice is reduced, and bone
marrow iron stores are absent [33], which could interrupt
erythropoiesis by limiting iron availability.
The important role of TfR1 in iron acquisition by
erythroblasts is also supported by studies in the zebraﬁsh
model system. Zebraﬁsh expresses two TfR1 genes, TfR1a
and TfR1b [35]. TfR1b is expressed primarily in non-
erythroid tissues, and genetic ablation of TfR1b causes
growth retardation and brain necrosis without adversely
aﬀecting hemoglobinization. In contrast, TfR1a is expressed
speciﬁcally in erythroid precursor cells, and its ablation
causeshypochromicmicrocyticanemia[35].Sincemammals
express a single TfR1 gene ubiquitously, which is responsible
for transferrin iron uptake in all tissues including erythroid
tissues, it is not surprising that disruption of the TfR1
gene in mice aﬀects both erythropoiesis and neurologic
development, and deletion of TfR1 in mice is embryonically
lethal [38].
Mitoferrin 1 is the principle iron importer on the
inner membrane of mitochondria for erythroblasts. It is
highly expressed in hematopoietic tissues, and deﬁciency of
mitoferrin 1 impairs iron incorporation into heme, resulting
in hypochromic anemia and erythroid maturational arrest in
zebraﬁsh [36, 37] .T h er o l eo fm i t o f e r r i n( M f r n )h a sb e e n
studied in erythroblasts generated from Mfrn−/− murine
embryonic stem cells, which showed maturation arrest with
severely impaired incorporation of 55Fe into heme [36].
4. Iron SulfurCluster (Fe-S)
Biogenesis for Erythropoiesis
Iron sulfur clusters (Fe-S) are synthesized in human cells
by a mitochondrial machinery and also by an independent
cytosolic machinery, which involve at least 20 proteins inAdvances in Hematology 3
total, for review see [39]. In mitochondria, ISCS and ISD11
form a complex of cysteine desulfurase to provide the sulfur
needed for initial Fe-S formation. It is thought that frataxin
provides the iron by binding iron loosely to an acidic ridge
[40]. Fe-S clusters are assembled upon scaﬀold proteins,
which include ISCU [41], NFU [42], and ISCA [43]. In
cytosol, the cytosolic forms of ISCS and ISD11 (c-ISCS and
c-ISD11) provide sulfur [44] ,a n di r o nm a yb ea c q u i r e d
from the cytosolic iron pool, perhaps aided by a chaperone
or cytosolic frataxin [45, 46]. In the cytosol, clusters are
assembled upon various scaﬀolds including c-ISCU, c-NFU,
c-ISCA, IOP1, for review see [39, 47], and NBP35 [48].
Under conditions that impair mitochondrial Fe-S cluster
synthesis, iron is imported into mitochondria with high
priority,whichinturnresultsincytosolicirondeﬁciencyand
impairment in cytosolic Fe-S cluster synthesis [41, 44, 49].
As described above, IRP1 is a dual functional enzyme,
which is activated when deprived of its [4Fe-4S] cluster
to bind to IRE elements in mRNAs and regulate protein
translation. Due to the importance of IRP proteins in
iron homeostasis and the involvement of Fe-S clusters
in modulating IRP1 activity, the process of Fe-S cluster
biogenesis is actually central to the regulation of mammalian
cellular iron homeostasis [39]. Defects in human Fe-S cluster
biogenesis cause many diﬀerent diseases, including anemia
[25, 47, 50]. Recent studies have revealed that a number of
proteins in mitochondrial Fe-S cluster synthesis are required
for successful erythropoiesis, including ABCB7, GLRX5,
ISCA1-2, and C1orf69, the mammalian ortholog of Iba57.
ABCB7 is an ATP-binding cassette (ABC) transporter
located on the inner membrane of mitochondria, for review
see[51–53],whichisessentialtohemesynthesisanderythro-
poiesis, as revealed by development of sideroblastic anemia
in patients with ABCB7 mutations [54–56]. The ABCB7
deﬁciency results in iron accumulation in mitochondria,
reduced heme synthesis in erythrocytes and ineﬀective ery-
thropoiesis. Perhaps due to its high expression in cerebellum
in addition to bone marrow, patients with ABCB7 deﬁciency
also have ataxia [57, 58]. Atm1, the ABCB7 homologue in
yeast, has been thought to be a member of the proposed Fe-S
cluster export machinery in mitochondrial membranes. The
compound exported by Atm1 was originally hypothesized
to be an Fe-S cluster, for review see [52, 59]. As research
progressed, and Fe-S synthesis proteins were identiﬁed in
the cytosol, it was hypothesized that the iron for cytosolic
Fe-S assembly was acquired from the cytosol, but that the
Atm1 substrate contained a speciﬁc type of sulfur that
was required for cytosolic Fe-S assembly, for review see
[60]. In human cells, although its activity is not required
for Fe-S cluster biogenesis in mitochondria, the unknown
substrate transported by ABCB7 appears to be required for
the maintenance of iron homeostasis in cytosol, which may
in turn aﬀect the Fe-S cluster biogenesis process in cytosol
[39]. Another possibility is that the product exported by
ABCB7 perhaps represents a gauge of mitochondrial iron
status that contributes to regulation of mitochondrial iron
homeostasis. When production or export of this unknown
ABCB7 substrate is disturbed, the cell responds as though
mitochondria were iron depleted, and eﬀorts to rectify the
misperceived state of mitochondrial iron depletion result
in actual mitochondrial iron overload and cytosolic iron
deﬁciency [58, 61, 62].
ABCB7 function is somehow required for erythropoiesis,
as ABCB7 deﬁcient animals develop anemia. But it is thus far
unclearatwhichstepABCB7functionaﬀectshemesynthesis.
It has been suggested that ABCB7 may physically interact
with ferrochelatase and somehow support its activity [54].
Another possible point where ABCB7 may exert its eﬀect
is upon erythroid ALAS2, the enzyme that catalyzes the
ﬁrst step of heme biosynthesis, which contains a 5  IRE in
its transcript. ABCB7 deﬁciency activates the IRE binding
activity of IRP proteins in cytosol, which in turn may inhibit
the translation of ALAS2 [62] .T h em o l e c u l ee x p o r t e db y
ABCB7 does not necessarily have to be an Fe-S cluster or
its components. Based on the ﬁnding that Mdl1, an ABC7-
like transporter, is actually a mitochondrial peptide exporter
[64], and that the substrate of Atm1 proteins is cysteine rich
[65], it is possible that this substrate may be a cysteine-rich
small peptide, which signals the rest of the cell about the
mitochondrial iron status. It would also be possible that the
Atm1 substrate is a sulfur compound in yeast, which may
combine with iron to form Fe-S clusters in cytosol [60].
Hemebiosynthesis isachievedby eightenzyme-catalyzed
steps (Figure 1). The ﬁrst step of heme synthesis, the con-
densation of succinyl-CoA and glycineinto 5-aminolevulinic
acid (ALA), is catalyzed by ALAS2 in the mitochondrial
matrix of erythroid precursor cells. ALA is exported to the
cytosol, and the subsequent six steps of heme synthesis take
place either in the cytosol or in the intermembrane space of
mitochondria.Thehemeintermediate,protoporphyrinIX,is
imported into mitochondria. In the last step, ferrochelatase
inserts an iron into protoporphyrin IX to produce heme
[10, 66].
Frataxin is thought to be the potential iron donor
for Fe-S cluster biogenesis in mitochondria [51], and loss
of functional frataxin alters heme synthesis pathway in
mammalian cells [67] and in a mouse model for the human
disease, Friedreich ataxia [68]. Frataxin may also provide
iron to the ferrochelatase-catalyzed last step in heme biosyn-
thesis, in which ferrous iron is inserted into protoporphyrin
IX [69, 70]. However, Friedreich ataxia patients do not
demonstrate signiﬁcant anemia, suggesting frataxin is not
essential for heme synthesis and erythropoiesis, or that
frataxin-deﬁciency is not present in erythropoietic tissues
of Friedreich ataxia patients. In a frataxin deﬁcient mouse
model and in Friedreich ataxia patient lymphoblast cells,
heme production was not reduced, but the heme derivatives,




the methyl group at C-8 of heme O is hydroxylated by
monooxygenase that depends on ferredoxin to generate
heme A. [71]. The decrease in [2Fe-2S]-ferredoxin activity
caused by frataxin deﬁciency may interrupt the conversion
of heme O to heme A.
GLRX5, the human ortholog of yeast GRX5, for review























Figure 1: The Fe-S biogenesis proteins, ISCA and C1orf69 (Iba57 homologue), may impact heme synthesis by aﬀecting the production of
succinyl-CoA, a substrate of heme synthesis. This proposed role is highly hypothetical and has not been shown in organisms that perform
erythropoiesis. The ISCA- C1orf69 complex provides Fe-S clusters for lipoate synthase as suggested in yeast [63], which produces lipoate
for a subunit of the pyruvate dehydrogenase complex (PDC). PDC converts pyruvate into acetyl-CoA, which enters the citric acid cycle to
form citrate. The ISCA- C1orf69 complex provides the Fe-S cluster for mitochondrial aconitase, which converts citrate to isocitrate, which
leads to synthesis of succinyl-CoA, a substrate for the ﬁrst step in heme biosynthesis. All proteins are in the matrix. Other Fe-S proteins
important in heme biosynthesis are ferrochelatase, which is unstable without its [2Fe-2S] cluster, and IRP1, which represses synthesis of
ALAS2 when it lacks an Fe-S cluster. In the heme synthesis pathway, succinyl-CoA and glycine are condensed into 5-aminolevulinic acid
(ALA). The subsequent six steps take place either in cytosol or in the intermembrane space of mitochondria. The last step is the insertion of
a ferrous iron into protoporphyrin IX by ferrochelatase (FECH) to result in heme formation.
conserved monothiol glutaredoxins that are essential to Fe-
S cluster biogenesis in yeast, plants, and mammals [75–
77], and GLRX5 deﬁciency caused sideroblastic anemia
in an Italian patient [74]. Thus far, several monothiol
glutaredoxin proteins have been shown to assemble an
intermolecular [2Fe-2S] cluster that is ligated between a
glutaredoxin dimer and by two glutathione peptides in vitro
[78–80], and it has been suggested that GRX5 homologues,
including the human GLRX5, could serve as an alternative
scaﬀold protein that may deliver Fe-S clusters to a speciﬁc
subgroup of target proteins [81]. As previously discussed,
the molecule exported by ABCB7 is likely produced or
dependent on the mitochondrial Fe-S biogenesis machinery.
We hypothesize that this unknown molecule may signal the
rest of the cell about the status of iron in mitochondria
and lead to transcriptional remodeling. We postulate that
the disturbance of the potential mitochondrial to nuclear
signalingpathwaycausesironaccumulationinmitochondria
and relative iron deﬁciency in cytosol [39]. Similar to the
eﬀects caused by many mitochondrial Fe-S synthesis defects,
GLRX5deﬁciencyalsoresultsinmitochondrialironoverload
[74, 81]. The IRE- binding activities of IRP proteins are
elevated, which in turn inhibits the translation of mRNAs
that contain 5 IREs. In addition, GLRX5 is intimately
involvedinerythropoiesisasrevealedbythefollowingresults
[81]; ﬁrst of all, GLRX5 is highly expressed in bone marrow
and particularly in erythroid precursor cells, as shown by
both bioinformatics data and in situ hybridization; secondly,
GLRX5 expression is induced during erythroid diﬀerentia-
tion, in association with two other heme synthesis proteins,
ALAS2 and ferrochelatase [82, 83]; and thirdly, GLRX5
deﬁciency caused a sideroblastic anemia in a human patient
[74] and anemia in zebraﬁsh [76]. Finally, GLRX5 deﬁciency
decreases heme synthesis and hemoglobinization [81]. Dur-
ing erythroblast diﬀerentiation, ALAS2, ferrochelatase and
GLRX5 expression are all upregulated in order to synthesize
large amounts of heme [81]. We postulate that GLRX5
and other essential mitochondrial Fe-S biosynthesis proteins
continue to produce and export a factor that signiﬁes the
mitochondrial iron homeostasis is normal. General cellular
iron homeostasis is not disturbed, and IRE binding activity
of IRP1 remains low. ALAS2 mRNA that contains a 5  IREAdvances in Hematology 5
is therefore translated into protein adequately. Based on the
facts that ferrochelatase protein is readily degraded in the
absenceofitsFe-Scluster[82]andthatferrochelataseprotein
levels are substantially decreased in GLRX5 deﬁcient patient
lymphoblasts [81], we have hypothesized that GLRX5 may
deliver the preassembled [2Fe-2S] cluster to ferrochelatase.
Thus, normal GLRX5 activity allows expression of ALAS2
and ferrochelatase to increase during hemoglobinization for
erythropoiesis [81]. On the other hand, GLRX5 deﬁciency
leads to a transcriptional increase of ferroportin (FPN1)
mRNA, including the FPN1a and 1b forms [81]. The
FPN1b mRNA is expressed in erythroblasts and duodenal
mucosal cells. It does not contain a 5 IRE, and IRP proteins
therefore cannot repress its translation [84]. The increased
FPN1 protein levels in erythroblasts probably lead to severe
cytosolic iron deﬁciency. This erythroid-speciﬁc expression
of two novel transcripts, the IRE-containing ALAS2 and the
nonIRE containing FPN1b, may explain why the phenotype
ofGLRX5deﬁciencymanifesteditselfmainlyintheerythroid
tissues of a human patient [81].
Isa1andIsa2,theyeasthomologuesofISCA1andISCA2,
are thought to function as alternative scaﬀold proteins that
can substitute for the Isu scaﬀold in the mitochondrial Fe-
S cluster biogenesis of yeast [51]. It was recently discovered
that expression of these putative scaﬀold proteins is induced
in animals when heme biosynthesis enzymes are induced
[83]. In yeast, Isa1 and Isa2 may receive an Fe-S cluster
intermediate from Isu, the dominant scaﬀold, and assemble
Fe-S clusters for a subgroupof target proteins [85], including
mitochondrial aconitases and several enzymes of the radical
S-adenosylmethionine (SAM) Fe-S protein family, including
biotinsynthaseandlipoatesynthaseinyeast[85].Theradical
SAM superfamily comprises more than 2800 proteins that
chelate [4Fe-4S] clusters. These enzymes use the strong
reducing potential of a low potential [4Fe-4S] cluster to
generate a powerful oxidizing agent, the 5 -deoxyadenosyl
r a d i c a l ,f r o mS A M ,f o rr e v i e ws e e[ 86]. A newly identiﬁed
yeast protein, Iba57, facilitates this process by physically
interacting with Isa1-2. Although it is still unknown how
theywork,Isa1,Isa2,andIba57formacomplexandassemble
Fe-S clusters for mitochondrial aconitase and radical SAM
Fe-S proteins in yeast [63].
In addition, a recent large-scale gene expression analysis
has revealed that ISCA1 and ISCA2, the human homo-
logues of Isa1 and Isa2, and the human Iba57-like protein,
C1orf69, are required for heme biosynthesis in animals
[83]. Experimental results have demonstrated that, similar
to other heme synthesis enzymes, ISCA1 and C1orf69 are
induced during erythroid diﬀerentiation. In situ hybridiza-
tion analysis using zebraﬁsh embryos shows that C1orf69 is
speciﬁcally expressed in hematopoietic tissues. Knockdown
of either ISCA1 or C1orf69 reduces heme production and
hemoglobinization, and thus causes profound anemia in
zebraﬁsh. Although the mechanism is not known, it is
hypothesized that ISCA1-2 and C1orf69 may assemble
Fe-S clusters for mitochondrial aconitase and for lipoate
synthase, which may produce a cofactor for the pyruvate
dehydrogenase complex (PDC) [83]. Both PDC, the enzyme
responsible for converting pyruvate to acetyl-CoA to enter
the citric acid cycle, and aconitase, a citric acid cycle
enzyme, are directly involved in producing succinyl-CoA, a
substrate in the ﬁrst step of heme synthesis catalyzed by ALA
synthase, in which succinyl-CoA and glycine are condensed
into the product, 5-aminolevulinate. Their potential eﬀects
on succinyl-CoA synthesis might partially explain why and
how ISCA1-2 and C1orf69 proteins are important in heme
biosynthesis (Figure1).Even thoughIsa and Iba57 havebeen
shown to be required for activity of lipoate synthase in yeast
[63], it is not known whether ISCA and C1orf69 have similar
roles in activating PDC of heme-synthesizing animals.
Along with their ﬁndings about ISCA and C1orf69,
investigators also identiﬁed other candidate genes that are
essential for heme synthesis [83], including SLC25A39,
which is orthologous to yeast MTM1. This protein is impli-
cated in mitochondrial iron homeostasis, and its mutation
leads to misincorporation of iron to Mn-SOD and iron
overload in mitochondria [87–89]. Based on the phenotypes
of MTM1 and GLRX5, the authors predicted that SLC25A39
may be involved in Fe-S biogenesis. Furthermore, this large-
scaleexpressionstudyhasgeneratedacollectionofcandidate
genes that are probably required for heme biosynthesis [83],
some of which may be uncharacterized Fe-S biogenesis genes
in erythroblasts.
In summary, Fe-S biogenesis is required to execute
several steps of heme synthesis, particularly when large
amounts of heme are needed for hemoglobinization during
erythropoiesis. Multiple heme synthesis enzymes deﬁnitely
need Fe-S for activity, such as ferrochelatase whereas some
others need Fe-S cofactors to potentially provide substrates
for heme synthesis, for example PDC and mitochondrial
aconitase [83], and others such as ALAS2 can be eﬃciently
translated only when cytosolic Fe-S biogenesis is intact.
In principle, since the Fe-S biogenesis pathway involves at
least 20 proteins, any of these Fe-S biogenesis proteins may
impact heme synthesis. But so far only GLRX5, ABCB7, and
the potential ISCA1-C1orf69 complex are clearly demon-
strated by hematopoietic phenotypes in model systems and
diseases to be important in heme synthesis. Interestingly,
they (GLRX5, ABCB7, ISCA1 and C1orf69) are all highly
expressed in hematopoietic tissues, compared to other Fe-S
synthesis proteins which are more evenly distributed among
many tissues, such as ISCS and ISCU. Moreover, all of them
except ABCB7 are induced during erythroid diﬀerentiation,
similar to the heme synthesis enzymes.
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